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Most antidepressants suppress rapid eye movement (REM) sleep, which is thought to be important to
brain function, yet the resulting REM sleep restriction is well tolerated. This study investigated the
impact of antidepressants with different mechanisms of action, such as selective serotonin reuptake
inhibitors (SSRIs) and tricyclic antidepressants (TCA), on the regulation of REM sleep in rats. REM sleep
was ﬁrst demonstrated to be homeostatically regulated using 5, 8 and 10 h of REM-sleep speciﬁc re-
striction through EEG-triggered arousals, with an average of 91 ± 10% of lost REM sleep recovered
following a 26e29 -hour recovery period.
Acute treatment with the antidepressants paroxetine, citalopram and imipramine inhibited REM sleep
by 84 ± 8, 84 ± 8 and 69 ± 9% respectively relative to vehicle control. The pharmacologically-induced
REM sleep deﬁcits by paroxetine and citalopram were not fully recovered, whereas, after imipramine
the REM sleep deﬁcit was fully compensated. Given the marked difference between REM sleep recovery
following the administration of paroxetine, citalopram, imipramine and REM sleep restriction, the ho-
meostatic response was further examined by pairing REM sleep speciﬁc restriction with the three
antidepressants.
Surprisingly, the physiologically-induced REM sleep deﬁcits incurred prior to suppression of REM sleep
by all antidepressants was consistently recovered. The data indicate that REM sleep homeostasis remains
operative following subsequent treatment with antidepressants and is unaffected by additional phar-
macological inhibition of REM sleep.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Most antidepressants inhibit rapid eye movement (REM) sleep
in animals and humans. In particular, selective serotonin re-uptake
inhibitors (SSRIs), such as citalopram and paroxetine, the mainstay
of depression treatment, are potent inhibitors of REM sleep when
administered acutely, sub-chronically or chronically (reviewed in
Palagini et al., 2013). Relatively few antidepressants offer psychi-
atric beneﬁts without causing reductions in REM sleep (Sharpley
and Cowen, 1995; Palagini et al., 2013) and extended courses of
antidepressant treatment are well tolerated without the ill effects
typically reported in experimental REM sleep deprivation, Windlesham, Surrey, GU20
rthy).
r Ltd. This is an open access articleparadigms (Vertes and Eastman, 2000; Siegel, 2001).
The most common sleep-electroencephalography (EEG)
markers of major depressive disorder (MDD) include shorter la-
tency to the onset of REM sleep, increased REM sleep time and
increased density of rapid eye movements during REM sleep;
reduced sleep efﬁciency and reduced total sleep time slow wave
sleep (Pillai et al., 2011). Paradoxically, the changes in REM sleep
parameters observed in MDD are similar to the effects seen
following REM sleep restriction in humans and animals (Palagini
et al., 2013; Kupfer et al., 1981; Coble et al., 1976; Lucidi et al.,
1996). The strong correlation between REM sleep inhibition and
drug activity has led to the hypothesis that suppression of REM
sleep may contribute to an antidepressant action (Vogel, 1983). The
antidepressant efﬁcacy of REM-speciﬁc sleep restriction was tested
by inducing awakenings upon the appearance of the ﬁrst signs of
REM sleep. REM sleep restriction alone was sufﬁcient to improveunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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et al., 1975).
REM sleep is controlled by both circadian and homeostatic
mechanisms (Brunner et al., 1990; Dijk and Czeisler, 1995; Wurts
and Edgar, 2000). REM sleep homeostasis can be tested through
methods that selectively inhibit REM sleep manifestation via EEG-
driven feedback methods, which provide a waking stimulus only if
an animal enters REM sleep as determined in real-time from EEG
and EMG measures (53 Wurts and Edgar, 2000; 126 Rechtschaffen
and Bergmann, 1995). Selective REM sleep deprivation leads to a
progressive increase over time in attempts to enter REM sleep and
REM sleep-enriched sleep following release from deprivation in
both animals and humans (Vogel, 1975; Shea et al., 2008). Ho-
meostatic control of REM sleep has even been shown to persist in
the absence of circadian control (Wurts and Edgar, 2000). The
conservation of REM sleep time suggests its importance in physi-
ological processes and its homeostatic maintenance may be rele-
vant to the antidepressant action of REM sleep restriction.
These observations raise the question: Is REM sleep inhibition
caused by antidepressant therapeutics functionally equivalent to
physiologically-induced forms of selective REM sleep deprivation?
Antidepressants that suppress REM sleep potentially alter the
neurochemical control mechanisms of REM sleep homeostasis.
Many of the neurochemical circuits involved in controlling REM
sleep onset and maintenance have been identiﬁed, with mutually
inhibitory monoaminergic, GABAergic and glutamatergic systems
(reviewed in Luppi et al., 2013). The mechanisms underlying REM
sleep homeostasis however remain largely unknown. In the current
study the interaction between a pharmacological and physiologi-
cally induced REM sleep loss was examined.
The homeostatic response following REM sleep inhibition by
antidepressants may differ to the homeostatic response caused by a
physiological REM sleep restriction. To address this possibility, we
paired REM speciﬁc sleep restriction with antidepressant treat-
ments and closely evaluated interactions between the two mech-
anisms of REM sleep suppression. Two selective serotonin reuptake
inhibitors (SSRIs), paroxetine and citalopram, and the tri-cyclic
antidepressant (TCA) imipramine were tested alone and in the
presence of increased REM sleep homeostatic pressure.
2. Methods
2.1. Subjects
All procedures were carried out in accordance with the UK
Animals Scientiﬁc Procedures Act (1986) and associated guidelines,
the European Communities Council Directive of 24 November 1986
(86/609/EEC) and passed the Lilly UK ethical review. In accordance
with the principles of the 3Rs, all efforts were made to minimise
animal suffering, to reduce the number of animals used, to reﬁne
procedures and utilise alternatives to in vivo techniques, if available.
Male Wistar rats sourced from Charles River, Kent, UK were used as
subjects for all experiments. At the time of surgery animals were
approximately 70e80 days old and weighed 250e300 g.
2.2. Animal preparation and surgery
Rats were anesthetized (2% isoﬂurane in 100% oxygen) and
surgically prepared with a cranial implant for chronic EEG and
electromyogram (EMG) recordings. Body temperature and loco-
motor activities were monitored via a miniature transmitter
(Minimitter PDT4000G, Philips Respironics, Bend, OR) placed in the
abdomen. The cranial implant consisted of stainless steel screws (2
frontal [þ3.5 AP from bregma, ±2.0 ML] and 2 occipital [6.5 AP,
±5.2 ML]) for collection of EEG signals. For EMG recordings twoTeﬂon-coated stainless steel wires positioned under the nuchal
trapezoidmuscles. The implant assembly was afﬁxed to the skull by
the combination of the EEG recording screws, cyanoacrylate
applied between the hermetically sealed implant connector and
skull, and dental acrylic. An analgesic (buprenorphine 0.05 mg/kg)
was administered subcutaneously pre-operatively, at the end of the
surgery day, and the morning of the ﬁrst post-operative day. To
provide additional pain relief, meloxicam 0.15 mg/kg was admin-
istered orally twice daily for 6 days post-surgery. The antibiotic
cephalexin 20 mg/kg was administered orally 24 h prior to and
immediately before surgery, and twice daily for 7 days after
surgery.2.3. Housing environment
After a 4-week recovery period, animals were housed individ-
ually in custom-designed sleep deprivation chambers for the
duration of the experiment.
Sleep restriction chambers consisted of a rotatable cylinder
(39.7 cm diameter by 32.1 cm length, 637.2 cm2 ﬂoor space) con-
structed of plexiglass rods, positioned horizontally inside a plex-
iglass frame. Cranial implants were connected to ultra-low-torque
slip-ring commutators (Hypnion, Inc., Lexington, MA, USA) by
metal coil reinforced ﬂexible cables, allowing unrestrained move-
ments. EEG/EMG-signal based sleep restriction used real-time
feedback of ongoing sleep/wake states to prevent sleep, similar to
the methods described by (Wurts and Edgar, 2000).
The study was conducted in a sound-attenuated, light and
temperature-controlled recording room, to control for sensory
modalities known to affect sleep. Each cage was provided with an
infrared light source and digital video camera to allow continuous
remote visual monitoring. A 24-hr light-dark cycle (LD 12:12) was
maintained throughout the study using ﬂuorescent light to act as a
zeitgeber (ZT). Light intensity averaged 35e40 lux at mid-level
inside the cage. Food and water were available ad libitum and the
ambient temperature was maintained at 21 ± 1 C with a relative
humidity of approximately 50%.2.4. Automated EEG/EMG data collection and sleep staging
Ampliﬁed EEG 10,000-fold (band-pass ﬁltered 1e30 Hz: Grass
Corp., Quincy, MA, USA) with an initial digitization rate of 400 Hz
and ampliﬁed EMG (band-pass 10e100 Hz, RMS integration) were
collected from the ﬁxed electrodes. Concurrently, body tempera-
ture and locomotor activity were recorded. SCORE2004™, an
automated sleep-wake and physiological monitoring system, was
used to record and determine vigilance states, as previously
described (Van Gelder et al., 1991; Seidel et al., 1995; Olive et al.,
1998; Phillips et al., 2012). Vigilance states were classiﬁed on-line
as NREM sleep, REM sleep, wake, or theta-dominated wake, every
10 s, using EEG period and amplitude feature extraction and ranked
membership algorithms. In addition to frequent on-line inspection
of the EEG and EMG signals, quality control of the data was assured
using a proprietary suite of programmes (SCOREVIEW™, Hypnion,
Inc., Lexington, MA) that allowed data quality of all variables to be
ﬂexibly scrutinized at the level of (i) individual visual examination
of raw EEG and EMG signals, (ii) individual hourlymean time series,
and (iii) group mean time series, using a combination of graphical
and statistical assessments. A fast Fourier transform was used to
calculate the spectral EEG power in each 10-s epoch in 0.1 Hz bins.
Telemetry measures (locomotor activity and body temperature)
were not part of the SCORE vigilance-state determination algo-
rithm; thus, sleep-scoring and telemetry data were concurrent but
independent measures.
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Citalopram (synthesized at Eli Lilly), paroxetine (Sigma Aldrich)
and imipramine (Zerenex Ltd) were formulated in pH-adjusted
methylcellulose 15 cP 0.25% vehicle. Compound was weighed us-
ing a Mettler Toledo AB104-S analytical balance then ﬁnely ground
and suspended into vehicle. The doses of 10 mg/kg citalopram,
5 mg/kg paroxetine and 7 mg/kg imipramine were administered
orally (PO).
The rationale for dose selectionwas as follows: A similar level of
pharmacological REM inhibition to the 8-h EEG-driven feedback
sleep restriction was selected for citalopram from a database of
dose response data of compounds given at ZT-5 (data not shown).
The doses of the remaining compounds were selected to match the
level of REM sleep inhibition of citalopram. Statistical analysis was
performed to determine the loss and recovery of sleep as a result of
each treatment and evaluate potential interactions between REM
sleep homeostasis and antidepressants. At least 7 days “washout”
preceded and followed any treatment and examination of normal
baseline activity relative to non-treated animals was performed
prior to entry into the study.
2.6. REM sleep restriction protocol
Rats underwent at least 48 hrs of undisturbed baseline
recording of sleep-wake patterns and before REM sleep restriction
of 5, 8 or 10 h’s duration starting ZT-0. Sleep and wake behaviours
were determined automatically in real time using SCORE-2004™.
Detection of REM sleep epochs by the SCORE2004™ program ac-
tivates a motor to roll the cylindrical chamber around its axis for 8 s
(265 of rotation at 11.5 cm/s), thereby initiating the righting reﬂex
and waking the rat. The rotation caused a vestibular reﬂex,
immediately awakening the rat.
In the studies combining REM sleep restriction with antide-
pressant administration, a REM sleep restriction period of 8 h was
chosen. This level of REM sleep restriction showed a clear REM
sleep deﬁcit, followed by a rebound. In addition, 4-h of the light
phase remained, during which the antidepressant drug treatments
most actively suppressed REM sleep.
2.7. Study design and statistical analysis methods
The dose response to REM sleep restriction studies were con-
ducted in distinct parallel groups, i.e., no animal was exposed to
more than one REM sleep restriction. A total of 51 Wistar rats were
used which at the start of the experiment were on average 131 ± 6
days old and weighing 487 ± 8.4 g (all values reported as
mean þSEM). The magnitude of sleep loss relative to non-sleep
restricted controls was calculated using a mixed model procedure
with length of REM sleep restriction as a ﬁxed effect. 24-h of the
undisturbed baseline was used as a covariate to represent prior
sleep history.
A within subject, full crossover, repeated measures study design
was used for each REM sleep restriction and antidepressant com-
bination experiment. A total of 53 Wistar rats, on average 138 ± 6
days old and weighing 484.3 ± 6.5 g at the start of each experiment,
were randomly assigned to treatment groups. Prior to any treat-
ment, animals were left undisturbed for 48-h to record a baseline
from which drug effects could be evaluated. REM sleep restriction
was performed between the hours of ZT-0 and ZT-8 and immedi-
ately following release from the REM sleep restriction, the rats were
dosed orally with active compound or vehicle control (ZT-8, i.e., 8-h
after lights on; Fig. 1). For drug administration, each animal was
removed from its cage for about 60e90 s to beweighed and treated.
Statistical analyses and plotting were performed using the SAS(version 9.2, SAS Institute, Inc., Cary, NC) software package and
SigmaPlot (version 12.5, Systat Software, Inc., San Jose California
USA, www.sigmaplot.com). The effects of sleep restriction and drug
were evaluated over the recording period as outlined in Fig. 1. The
following time periods were used: 0e8 h during the period of sleep
restriction; 8e12 h of light immediately following drug adminis-
trationwhen drug activity was maximal; and a ﬁnal recovery phase
between 12 and 36 h after the start of sleep restriction. Effects were
evaluated using mixed model analysis with the magnitude of REM
sleep restriction; drug treatment; and the interaction between the
two factors as ﬁxed effects with each subject acting as its own
control. Hourly differences to baseline were evaluated using two-
tailed repeated measures ANOVA with a Bonferroni correction.
Percentage deﬁcits were calculated relative to control from the
least squares means generated in the mixed model described. Re-
covery sleep was calculated from the differences generated in the
mixed model between treatment groups. The percentage recovery
is the proportion of additional sleep throughout the recovery
period relative to the deﬁcit induced by the REM sleep restriction.
For example, if a deﬁcit of 20 min is incurred and 15 min of this is
recovered by the end of 48 h, a 75% recovery has been achieved.
2.8. Sleep recovery modelling
Accumulation of sleep was calculated after treatment, relative to
the previous 24-h baseline. Bin ¼ 1 denotes the ﬁrst 60 min post-
treatment. Subsequent bins accumulate the change from baseline.
Thus, positive slopes imply more time in the vigilance state than
during the baseline e.g., recovery sleep, and a negative slope im-
plies less time in the state e.g., sleep loss. Recovery sleep was
modelled using an exponential decay process previously described
(Stephenson et al., 2015).
[tNREM, tREM] ¼ Rspan $ (1exp[t/t]) þ Y0, and
tWAKE ¼ Rspan $ exp[t/t] þ T0
Three variables: Y0, the initial sleep deﬁcit; T0, the response
asymptote; and t, the response time constant were used to describe
the model. Rspan, the quantity of recovered sleep is equivalent to
Y0eT0. Analysis was performed using the Python 3.4 Scipy module
(Jones et al., 2001) and the curve_ﬁt function. Regressions were
provided to initial estimates for Y0 but not constrained as in the
Stephenson et al. analysis (Stephenson et al., 2015). The charac-
teristic rate of rebound, t, is the exponential time constant of the
response and is the time in hours to complete 1/e z 0.632 of
Rspan).
3. Results
Sleep was evaluated over 72 h, including an undisturbed base-
line period 24 h prior to treatment. During the baseline period, the
rats displayed a clear 24-h (circadian) rhythm in their sleep that
was consistent between treatment groups (Fig. 2A and C).
3.1. REM sleep restriction
EEG-driven feedback REM sleep restriction reduced the total
amount of REM sleep from 5 to 10% to between 0 and 3% of the
recording time across the range of restriction lengths. REM sleep
time during the REM sleep restriction, which reﬂects number of
attempts to enter REM sleep, increased linearly over the course of
the restriction protocol (Fig. 2A). A mean REM sleep debt of
13.1 ± 1.6, 16.0 ± 2.2 and 37.3 ± 4.3 min was accumulated over
control at 5, 8 and 10 h of REM sleep restriction respectively
Fig. 1. Study protocol showing 12 h light-dark schedule and relative times of REM sleep restriction onset (ZT-0) and drug treatment (ZT-8). Post-treatment measurements are
broken down relative to the protocol and light-dark cycle to yield 5 distinct periods following: 0e8 h; 8e12 h; 12e24 h; 24e36 h and 26e48 h. Corresponding periods in the
baseline were used in the analysis: 24 to 18 h; 18 to 12 h; 12 to 0 h; 24 to 12 h and 12 to 0 h.
Fig. 2. Minutes spent in REM sleep per hour. (A) and cumulative hourly differences from baseline (B) with a REM speciﬁc sleep restriction protocol, beginning at the red vertical line
0 (grey, N ¼ 11), 5 (green, N ¼ 12), 8 (blue, N ¼ 14) and 10 (red N ¼ 14) hours of sleep restriction were given starting at ZT-0 (Data presented as mean and standard error of the
mean). The REM sleep deﬁcit elicited by the restriction leads to a subsequent rebound that compensates for all lost sleep at each length of sleep deprivation. NREM sleep time (C)
and cumulative hourly differences from baseline (D) show that total NREM sleep time is largely unaltered by the protocol.
A. McCarthy et al. / Neuropharmacology 108 (2016) 415e425418(Fig. 2B), representing a reduction of 64 ± 9, 69 ± 8 and 60 ± 10% of
REM sleep in the equivalent baseline light period. Release from
REM restriction resulted in a prolonged elevation of REM sleep, in
proportion to REM sleep loss. The elevation of REM sleep during the
recovery phase compensated between 71% and 103% of REM sleep
lost during the restriction, averaging 91 ± 10% across all studies. The
total time in NREM sleep (Fig. 2C and D) was not signiﬁcantlyaffected relative to the non-sleep restricted control group, although
in the ﬁrst hour of sleep restriction a deﬁcit in NREM sleep was
elicited by the presence of the technicians. Interestingly, NREM
bout sleep lengths were increasingly shortened as time in REM
sleep restriction increased (Supplementary Fig. 1).
The rate of REM sleep recovery was estimated using an expo-
nential saturating function. Each REM sleep restriction length was
A. McCarthy et al. / Neuropharmacology 108 (2016) 415e425 419modelled independently (Table 1) and the model parameters rep-
resenting the zero-cross deﬁcit (Y0), recovery rate constant (t) and
asymptotic offset (T0) were evaluated. REM sleep deprivation
resulted in full recovery, resulting in asymptotic offsets (T0) that
were not signiﬁcantly different to 0. Equivalent values for the re-
covery rate constant were also found at each dose level of REM
sleep restriction; therefore increasing REM sleep deprivation only
altered the initial deﬁcit parameter.3.2. Acute effects of antidepressants on REM sleep time under
baseline conditions
The effects of citalopram, paroxetine and imipramine were
evaluated under baseline conditions and following an 8 h REM
sleep restriction using the experimental design shown in Fig. 1.
REM sleep time during the undisturbed baseline period 24 h prior
to treatment was equivalent between treatment groups (data not
shown).
Under baseline conditions, all doses of antidepressant given at
ZT-8 inhibited REM sleep for the remaining 4 h of the light cycle
(Figs. 3e5A). Citalopram and paroxetine both resulted in an 84 ± 8%
reduction in REM sleep relative to vehicle controls (see Tables 2
and 3 for corresponding values in minutes of REM sleep),
whereas imipramine inhibited REM sleep by 69 ± 9% reduction,
relative to vehicle controls during the 8e12 h analysis period.
Following citalopram or paroxetine treatment, there was no
signiﬁcant recovery of REM sleep during the 12e48 h analysis time
period (Figs. 3 and 4C). Following citalopram administration, after
48 h a total of 96 ± 40% of the deﬁcit in REM sleep remained
(Table 2). Paroxetine was tested to generalise ﬁndings to the se-
lective serotonin reuptake inhibitor class and also showed no sig-
niﬁcant recovery, with a REM deﬁcit of 105 ± 25% remaining after
48 h (Table 3). In contrast, imipramine, a tri-cyclic antidepressant,
showed a full recovery of the REM deﬁcit incurred during the
12e48 h analysis time period (Fig. 5B), which accounted for
93 ± 28% of the REM sleep deﬁcit (Table 4).
REM sleep recovery was also modelled following pharmaco-
logical REM sleep inhibition (Table 1). The citalopram induced
deﬁcit was not fully compensated (T0 ¼ 14.1 ± 0.7 min) but an
equivalent recovery rate was estimated to REM sleep restriction
(tau ¼ 5.4 ± 2.3 h). Paroxetine also showed a lack of REM sleep
compensation (T0 ¼ 20.3 ± 0.6 min) and a similar recovery rate
constant (tau ¼ 3.7 ± 2.2 h). In comparison to the SSRI treatments,
imipramine showed a full recovery (T0¼ 3.5 ± 4.2) and signiﬁcantly
altered recovery rate constant relative to vehicle controls
(tau ¼ 28.0 ± 11.2 h). Although the onset of the compensatory REM
sleep period was clear following citalopram and paroxetineTable 1
Model parameters of the exponential recovery model of REM sleep. Y0 is the deﬁcit
constant (in hours). Signiﬁcance vs non-sleep restricted vehicle control was determin
0.001 < p < 0.01; ***p < 0.001.
REM sleep restriction length Y0
REM restriction 5 hr 25.2 ± 2.5***
REM restriction 8 hr 42.6 ± 1.3***
REM restriction 10 hr 46.7 ± 2.5***
Citalopram 25.1 ± 1.3
8 h REM restriction þ vehicle 26.9 ± 0.8***
8 h REM restriction þ citalopram 41.4 ± 0.8***
Paroxetine 29.3 ± 3.7*
8 h REM restriction þ vehicle 29.9 ± 1.1*
8 h REM restriction þ paroxetine 43.4 ± 0.7**
Imipramine 25.6 ± 8.1**
8 h REM restriction þ vehicle 33.7 ± 0.8***
8 h REM restriction þ imipramine 46.0 ± 7.0***treatment, the inﬂection point (Y0) following imipramine treatment
was less so (Figs. 5C and D). The onset point of recovery was sys-
tematically increased to evaluate the effect of the choice of inﬂec-
tion (Y0) and shown to decrease from 28.0 ± 11.2 with choice of
onset 4 h after treatment to 18.1 ± 6.2 with choice of onset 7 h after
drug administration. Subsequent increases in the inﬂection point
prevented the model from converging.3.3. Acute effects of antidepressants on REM sleep time in the
presence of increased REM sleep pressure
Each experiment included a REM speciﬁc sleep restriction dur-
ing the 8 h following lights on (ZT-0) with vehicle treatment as a
placebo control. REM speciﬁc sleep restriction induced a 75 ± 10,
74 ± 9 and 67 ± 4% reduction in REM sleep relative to the non-sleep
restricted control group in the citalopram, paroxetine and imipra-
mine experiments respectively (Figs. 3e5B). In each case, a rebound
in REM sleep occurred and after 48 h a total of 115 ± 28, 73 ± 19,
86 ± 21% of the deﬁcit in REM sleep was recovered (Tables 2e4).
The recovery rate constants for each of these studies were lower
than those of the sleep restriction dose response, although these
differences were not statistically signiﬁcant (post-hoc t-test
p ¼ 0.50, p ¼ 0.55, p ¼ 0.32 vs. 8 hr sleep restriction for the cit-
alopram, paroxetine and imipramine study respectively).
In the presence of homeostatic REM sleep pressure caused by
8 h of REM sleep restriction prior to treatment all antidepressants
elicited a similar deﬁcit in REM sleep to acute administration
without prior REM sleep restriction (Figs. 3e5B). In the case of
citalopram, a difference of only 2.7 ± 2.7 min (ANCOVA, p ¼ 0.33)
was found between the two groups. Paroxetine also gave an
equivalent reduction of REM sleep to the non-sleep restricted
group, with a difference of only 0.1 ± 2.4 min (ANCOVA, p ¼ 0.96)
during the 8e12 h analysis period. Finally, there was no signiﬁcant
difference between the REM inhibition of imipramine under con-
trol conditions and following REM sleep restriction (1.6 ± 2.7 min,
ANCOVA, p ¼ 0.57).
The homeostatic response to the 8 h REM sleep restriction was
still evident in each of the treatment groups regardless of which
antidepressant was administered (Figs. 3e5D). In the citalopram
experiment, a total 115 ± 28 and 104 ± 26% of REM sleep deﬁcit was
recovered in the vehicle and citalopram treated groups respec-
tively. During the period of REM sleep inhibition induced by cit-
alopram, between 8 and 12 h after the onset of REM sleep
restriction, REM sleep recovery from the sleep restriction continued
with a recovery of 23 ± 7% of the deﬁcit achieved during this time
period. There were no signiﬁcant interactions between citalopram
and REM sleep restriction at any time point analysed.at 0 h (in minutes), T0 is the ﬁnal deﬁcit (in minutes) and t is the recovery rate
ed using ANOVA and is denoted by the following symbols: * 0.01 < p < 0.05; **
T0 t
3.5 ± 3.8 6.5 ± 1.4
5.1 ± 3 8.0 ± 0.7
6 ± 2.7 6.3 ± 1.4
14.1 ± 0.7*** 5.4 ± 2.3
4.3 ± 0.8** 6.9 ± 1.1
12.2 ± 0.8*** 5.0 ± 1.0
20.3 ± 0.6*** 3.7 ± 2.2
7.8 ± 0.9* 7.0 ± 1.6
19.6 ± 0.7*** 9.1 ± 1.3
3.5 ± 4.2** 28.0 ± 11.2***
3.13 ± 0.5 5.9 ± 1.0
0.21 ± 3.7 21.5 ± 6.0***
Fig. 3. The effects of 10 mg/kg citalopram upon REM sleep with and without prior REM sleep debt. eCitalopram (red); e Vehicle control (pink); e REM sleep restriction followed by
citalopram administration (blue) and e REM sleep restriction control (light blue). Data presented as mean and standard error of the mean. (A) Hourly plot of total REM sleep time
with vehicle and citalopram administration at 8 h; (B) Hourly plot of total REM sleep time with vehicle and citalopram administration at 8 h following REM sleep restriction (RR,
0e8 h); (C) Accumulated REM sleep, relative to the baseline period 24 h prior, showing REM sleep effects of citalopram without prior REM sleep restriction; (D) Accumulated REM
sleep, relative to the baseline period 24 h prior, showing REM sleep effects of citalopram with prior REM sleep restriction. *p < 0.05 repeated measures ANOVA; (E) Analysis of
recovery from REM restriction (RR), citalopram (CIT), and the component of recovery from REM restriction (cRR) and citalopram (cCIT) attributed in the combination group.
*p < 0.05; **p < 0.01; ***p < 0.001 ANCOVA.
Table 2
Summary statistics from the mixed model analysis of REM restriction in combination with citalopram. Measurement periods are split into pre-deﬁned analysis periods.
Comparison [2-1] is the quantity of REM in the citalopram treated group relative to vehicle controlswithout REM sleep restriction (RR). Comparison [4-3] is the quantity of REM
in the citalopram treated group relative to vehicle controls in the REM sleep restricted condition. Comparison [3-1] is the quantity of REM in the sleep deprived group relative to
non-sleep deprived controls that received vehicle treatment. Comparison [4-2] is the quantity of REM in the sleep deprived group relative to non-sleep deprived controls that
received citalopram. Statistical signiﬁcancewas determined by repeatedmeasures ANCOVA, where baseline and datewere included as covariates and a Tukey adjustment used.
Signiﬁcance is denoted by the following symbols: * 0.01 < p < 0.05; ** 0.001 < p < 0.01; ***p < 0.001.
Condition Measurement period Minutes of REM sleep
Least squares means Comparison Difference from comparison group
[1] Vehicle 0e8 hrs (RR) 33.32 ± 2.32 [2-1] 0.06 ± 2.82
[2] Citalopram 33.26 ± 2.23 [4-3] 1.61 ± 3.21
[3] RR þ vehicle 8.26 ± 2.52 [3-1] 25.06 ± 3.19***
[4] RR þ citalopram 9.87 ± 2.22 [4-2] 23.39 ± 2.92***
[1] Vehicle 8e12 hrs 19.40 ± 1.54 [2-1] 16.43 ± 1.67***
[2] Citalopram 2.97 ± 1.50 [4-3] 19.14 ± 2.06***
[3] RR þ vehicle 27.86 ± 1.70 [3-1] 8.46 ± 1.98***
[4] RR þ citalopram 8.72 ± 1.51 [4-2] 5.75 ± 1.82***
[1] Vehicle 12e48 hrs 125.08 ± 5.01 [2-1] 0.43 ± 7.43
[2] Citalopram 125.51 ± 5.22 [4-3] 1.86 ± 7.49
[3] RR þ vehicle 147.53 ± 5.57 [3-1] 22.44 ± 7.69***
[4] RR þ citalopram 145.67 ± 4.89 [4-2] 20.15 ± 7.26***
[1] Vehicle 8e48 hrs 144.91 ± 4.62 [2-1] 15.72 ± 6.57*
[2] Citalopram 129.19 ± 4.59 [4-3] 18.82 ± 6.83**
[3] RR þ vehicle 173.84 ± 5.07 [3-1] 28.93 ± 7.03***
[4] RR þ citalopram 155.02 ± 4.41 [4-2] 25.83 ± 6.50***
A. McCarthy et al. / Neuropharmacology 108 (2016) 415e425420In the case of paroxetine, 91 ± 18 and 73 ± 19% respectively of
the REM sleep lost from the REM sleep restriction was recovered in
the paroxetine and vehicle treated groups respectively. Further-
more, during the 8e12 h analysis period, 25 ± 6 and 26 ± 7% of the
REM sleep deﬁcit induced by EEG-driven REM deprivation was
recovered in both the paroxetine and vehicle treatment groupsrespectively. As with citalopram, there were no interactions be-
tween paroxetine and REM sleep restriction recovery.
Finally, imipramine also showed no signiﬁcant difference in
REM inhibition between control conditions and following REM
sleep restriction. Imipramine inhibited REM sleep causing an
additional deﬁcit of 15.4 ± 2.0 min during the 8e12 h analysis
Fig. 4. The effects of 5 mg/kg paroxetine upon REM and NREM sleep with and without prior REM sleep debt. eParoxetine (red) e Vehicle control (pink) e REM sleep restriction
followed by Paroxetine administration (blue) e REM sleep restriction control (light blue). Data presented as mean and standard error of the mean. (A) Hourly plot of total REM sleep
time with vehicle and paroxetine administration at 8 h; (B) Hourly plot of total REM sleep time with vehicle and paroxetine administration at 8 h following REM sleep restriction
(RR, 0e8 h); (C) Accumulated REM sleep, relative to the baseline period 24 h prior, showing REM sleep effects of paroxetine without prior REM sleep restriction; (D) Accumulated
REM sleep, relative to the baseline period 24 h prior, showing REM sleep effects of paroxetine with prior REM sleep restriction. *p < 0.05 repeated measures ANOVA; (E) Analysis of
recovery from REM restriction (RR), paroxetine (PAR), and the component of recovery from REM restriction (cRR) and paroxetine (cPAR) attributed in the combination group;
*p < 0.05; **p < 0.01; ***p < 0.001 ANCOVA.
A. McCarthy et al. / Neuropharmacology 108 (2016) 415e425 421period, a 52 ± 5% reduction, relative to vehicle controls. Addition-
ally, imipramine did appear to interfere with REM sleep recovery
from the REM sleep restriction (Table 4).
The absence of recovery sleep resulting from SSRI treatment was
also still evident following REM sleep inhibition (Figs. 3 and 4E).
During the 12e48 h analysis time period there was no signiﬁcant
recovery in REM sleep as a result of paroxetine treatment. In
contrast, recovery REM sleep following imipramine treatment
combined additively with the recovery elicited by prior REM inhi-
bition (Fig. 5E). These results show that ﬁrstly REM sleep inhibition
by the citalopram or paroxetine was unaltered by the presence of
REM sleep pressure and secondly that citalopram had no impact
upon the recovery of REM sleep following physiological REM
restriction.
The recovery rates following the combination of both REM sleep
restriction and citalopram administration remained similar to both
citalopram and REM sleep restriction groups (Table 1). In contrast,
paroxetine administered following REM sleep restriction, elicited a
recovery rate that was greater than paroxetine alone but not
different to that of the REM sleep restriction group. Imipramine had
the clearest effect on the recovery rate constant. When adminis-
tered following REM sleep restriction, imipramine further
increased the REM deﬁcit but complete recovery was still achieved
albeit at a faster rate.
3.4. Acute effects of antidepressants on NREM sleep time under
baseline conditions and in the presence of increased REM sleep
pressure.
There were minimal effects of either REM sleep restriction or
citalopram on NREM sleep time. Without prior REM sleeprestriction, citalopram did not alter NREM sleep duration, relative
to vehicle controls when given at ZT-8 (Supplementary Fig. 2A). In
this experiment, EEG-driven feedback REM sleep restriction caused
a 10 ± 4% reduction of the NREM sleep prior to drug treatment.
NREM sleep continuity was unaltered by citalopram treatment
(Supplementary Fig. 2B). Relative to the loss of NREM during the
sleep restriction, a slight overshoot in the recovery of NREM sleep
occurred in the vehicle treated group, but NREM sleep time was
fully compensated in the citalopram treated group (Supplementary
Fig. 2C).
Paroxetine treatment at ZT-8 also did not alter NREM sleep time
or continuity, either when dosed alone or following REM sleep
restriction (Supplementary Figs. 3A and B). However, the recovery
of lost NREM sleep up to 36 h post treatment, which was unaltered
by the addition of paroxetine, showed full compensation of that lost
during the REM-sleep restriction (Supplementary Fig. 3C).
In addition to REM sleep inhibition, imipramine also reduced
NREM sleep time (Supplementary Fig. 4). Relative to vehicle con-
trols, imipramine induced a total loss of 16.8 ± 3.0 min, which was
16.2 ± 2.9% of the equivalent baseline period, when dosed at ZT-8.
Following REM sleep restriction this NREM sleep reduction did not
occur, resulting in an interaction effect between the treatments
(14.6 ± 4.4, ANCOVA, p ¼ 0.002). Finally, recovery of lost NREM
sleep resulting from imipramine was not recovered up to 36 h post
treatment, whereas the loss resulting from REM sleep restriction
was fully compensated.
4. Discussion
This study shows for the ﬁrst time that the inhibition of manifest
REM sleep by SSRI antidepressants occurs without augmenting or
Fig. 5. The effects of imipramine upon REM and NREM sleep with and without prior REM sleep debt. . eImipramine (red) e Vehicle control (pink) e REM sleep restriction followed
by Imipramine administration (blue) e REM sleep restriction control (light blue). Data presented as mean and standard error of the mean. (A) Hourly plot of total REM sleep time
with vehicle and imipramine administration at 8 h; (B) Hourly plot of total REM sleep time with vehicle and imipramine administration at 8 h following REM sleep restriction (RR,
0e8 h); (C) Accumulated REM sleep, relative to the baseline period 24 h prior, showing REM sleep effects of imipramine without prior REM sleep restriction; (D) Accumulated REM
sleep, relative to the baseline period 24 h prior, showing REM sleep effects of imipramine with prior REM sleep restriction. *p < 0.05 repeated measures ANOVA; (E) Analysis of
recovery from REM restriction (RR), imipramine (IMI), and the component of recovery from REM restriction (cRR) and imipramine (cIMI) attributed in the combination group;
*p < 0.05; **p < 0.01; ***p < 0.001 ANCOVA.
Table 3
Summary statistics of REM restriction in combination with paroxetine. Measurement periods are split into pre-deﬁned analysis periods. Comparison [2-1] is the quantity of
REM in the paroxetine treated group relative to vehicle controls without REM sleep restriction. Comparison [4-3] is the quantity of REM in the paroxetine treated group relative
to vehicle controls in the REM sleep restricted condition. Comparison [3-1] is the quantity of REM in the sleep deprived group relative to non-sleep deprived controls that
received vehicle treatment. Comparison [4-2] is the quantity of REM in the sleep deprived group relative to non-sleep deprived controls that received paroxetine. Statistical
signiﬁcance was determined by repeated measures ANCOVA, where baseline and date were included as covariates and a Tukey adjustment used. Signiﬁcance is denoted by the
following symbols: * 0.01 < p < 0.05; ** 0.001 < p < 0.01; ***p < 0.001.
Condition Measurement period Minutes of REM sleep
Least squares means Comparison Difference from comparison group
[1] Vehicle 0e8 hrs (RR) 36.04 ± 2.40 [2-1] 2.14 ± 2.94
[2] Paroxetine 38.18 ± 2.37 [4-3] 1.52 ± 3.23
[3] RR þ Vehicle 10.96 ± 2.63 [3-1] 26.60 ± 3.08***
[4] RR þ Paroxetine 9.44 ± 2.58 [4-2] 28.73 ± 3.09***
[1] Vehicle 8e12 hrs 23.41 ± 1.73 [2-1] 19.40 ± 1.69***
[2] Paroxetine 4.01 ± 1.72 [4-3] 19.26 ± 1.83***
[3] RR þ Vehicle 30.40 ± 1.85 [3-1] 6.99 ± 1.73***
[4] RR þ Paroxetine 11.14 ± 1.82 [4-2] 7.13 ± 1.78***
[1] Vehicle 12e48 hrs 135.35 ± 3.83 [2-1] 0.39 ± 2.23
[2] Paroxetine 134.96 ± 3.79 [4-3] 4.52 ± 4.79
[3] RR þ Vehicle 148.88 ± 4.17 [3-1] 13.53 ± 4.51**
[4] RR þ Paroxetine 153.40 ± 4.12 [4-2] 18.43 ± 4.68***
[1] Vehicle 8e48 hrs 159.05 ± 3.78 [2-1] 20.41 ± 4.85***
[2] Paroxetine 138.60 ± 3.76 [4-3] 13.68 ± 5.37*
[3] RR þ Vehicle 178.57 ± 4.19 [3-1] 19.52 ± 5.04***
[4] RR þ Paroxetine 164.89 ± 4.12 [4-2] 26.25 ± 5.15***
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logical REM sleep restriction. In contrast, an equivalent level of REM
inhibition induced by the TCA imipramine showed complete re-
covery adding to the compensatory response to prior REM sleep
restriction.4.1. Homeostatic recovery of REM sleep time following REM sleep
restriction
The recovery of REM sleep across the range of 5, 8 and 10 h of
REM sleep restrictions demonstrates the homeostatic regulation of
Table 4
Summary statistics of REM restriction in combination with imipramine. Measurement periods are split into pre-deﬁned analysis periods. Comparison [2-1] is the quantity of
REM in the imipramine treated group relative to vehicle controls without REM sleep restriction. Comparison [4-3] is the quantity of REM in the imipramine treated group
relative to vehicle controls in the REM sleep restricted condition. Comparison [3-1] is the quantity of REM in the sleep deprived group relative to non-sleep deprived controls
that received vehicle treatment. Comparison [4-2] is the quantity of REM in the sleep deprived group relative to non-sleep deprived controls that received imipramine.
Statistical signiﬁcance was determined by repeated measures ANCOVA, where baseline and date were included as covariates and a Tukey adjustment used. Signiﬁcance is
denoted by the following symbols: * 0.01 < p < 0.05; ** 0.001 < p < 0.01; ***p < 0.001.
Condition Measurement period Minutes of REM sleep
Least squares means Comparison Difference from comparison group
[1] Vehicle 0e8 hrs (RR) 36.72 ± 1.32 [2-1] 3.63 ± 1.93
[2] Imipramine 33.09 ± 1.28 [4-3] 2.84 ± 1.89
[3] RR þ vehicle 13.78 ± 1.23 [3-1] 22.94 ± 1.90***
[4] RR þ imipramine 10.94 ± 1.32 [4-2] 22.16 ± 1.94***
[1] Vehicle 8e12 hrs 22.90 ± 1.56 [2-1] 15.69 ± 2.09***
[2] Imipramine 7.21 ± 1.57 [4-3] 15.36 ± 1.96***
[3] RR þ vehicle 29.77 ± 1.43 [3-1] 6.87 ± 1.93***
[4] RR þ imipramine 14.41 ± 1.55 [4-2] 7.19 ± 2.20**
[1] Vehicle 12e48 hrs 126.77 ± 4.34 [2-1] 14.58 ± 4.41**
[2] Imipramine 138.30 ± 4.045 [4-3] 16.74 ± 4.06***
[3] RR þ vehicle 134.73 ± 4.01 [3-1] 10.28 ± 3.33***
[4] RR þ imipramine 151.47 ± 4.15 [4-2] 12.44 ± 3.63***
[1] Vehicle 8e48 hrs 147.44 ± 4.80 [2-1] 3.68 ± 4.93
[2] Imipramine 143.75 ± 4.57 [4-3] 1.6264 ± 4.64
[3] RR þ vehicle 165.31 ± 4.54 [3-1] 19.93 ± 4.84***
[4] RR þ imipramine 163.68 ± 4.69 [4-2] 17.87 ± 4.57***
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particularly in human studies, has been questioned due to a lack of
signiﬁcant recovery relative to the quantity of REM sleep (Endo
et al., 1998; Werth et al., 2002). However, in these studies
recording time was often limited, in contrast to the present study.
The current study found that, in male Wistar rats, REM sleep
returned to a theoretical set point in accordance with previous
studies inwhich the dynamics of this recoverywere evaluated as an
exponential decay process (Stephenson et al., 2015). Overall these
recovery data and the increased REM sleep attempts throughout
the physiological REM sleep restriction period show that, under
physiological conditions, REM sleep duration is tightly regulated
through homeostatic mechanisms.4.2. Acute suppression of time spent in REM sleep following
antidepressant treatment
The loss of REM sleep induced by the three antidepressant was
similar to that reported in previous studies in rats (Ivarsson et al.,
2005) and humans (Wilson et al., 2004). Acute REM sleep sup-
pression induced by antidepressants was not signiﬁcantly affected
by prior physiological REM sleep restriction and we conclude that
acute drug-induced suppression of REM sleep was independent of
REM sleep pressure. A previous study that combined REM sleep
restriction with the SSRI, escitalopram, also concluded that prior
REM sleep restriction did not signiﬁcantly alter the REM sleep in-
hibition effect of the compound (Katai et al., 2013). However, REM
sleep recovery was only observed over the ﬁrst 3 h of the recovery
period and signiﬁcant REM sleep homeostatic recovery was un-
likely to have occurred relative to the deﬁcit of a 72 h sleep
restriction.4.3. Homeostatic recovery of REM sleep time following acute
antidepressant treatment
We monitored REM sleep for at least 28 h following dosing,
which is beyond the expected action of the drugs: citalopram and
paroxetine have half-lives of approximately 3.7 h, and 2.2 h (un-
published Lilly data) respectively and imipramine has a half-life of
2.5 h (Dingell et al., 1964) in male Wistar rats. Administration ofcitalopram and paroxetine induced a REM sleep deﬁcit that was not
recovered over the following 28 h. Directly comparable data are not
reported for humans, although in a single dose study of another
SSRI (60 mg ﬂuoxetine) in healthy volunteers, it was reported that
despite an acute suppression of REM sleep in the ﬁrst night, no
signiﬁcant rebound of REM sleep was observed for the following
three nights (Feige et al., 2002). In rats, Benington and Heller (1995)
have also reported that ritanserin, a serotonin receptor antagonist,
and quinuclydinyl benzilate (QNB), a cholinergic agonist, suppress
REM sleep without a compensatory rebound.
Although a certain level of tolerance for lost REM sleep may
exist following pharmacological treatment, equivalent physiolog-
ical REM sleep inhibition showed a distinct rebound of REM sleep.
A full recovery of the REM sleep deﬁcit occurred following acute
imipramine administration without prior REM sleep restriction,
suggesting that in contrast to SSRIs, imipramine-induced REM
sleep inhibition increases REM sleep homeostatic pressure, similar
to REM sleep restriction. However, modelling of the recovery
process following imipramine administration showed a signiﬁ-
cantly slower recovery rate relative to physiological REM sleep
restriction.4.4. Homeostatic recovery of REM sleep following the combination
of selective REM sleep restriction and antidepressant treatment
Compensatory rebound following physiological sleep restriction
remained similar even in the presence of SSRI antidepressant
treatments. Furthermore, the additional loss of REM sleep induced
by the SSRIs was not recovered throughout the recording period
and the recovery rate constant remained unchanged despite the
additional sleep pressure. Studies, using the ‘ﬂower pot’ method to
induce selective REM sleep deprivation, paired with es-citalopram
treatment have previously been reported, although interactions
between the treatments on REM sleep recovery were not exten-
sively examined (Maudhuit et al., 1996; Prevot et al., 1996). Based
on our data, we propose that the mechanisms by which SSRIs
inhibit REM sleep are not tracked by the REM sleep homeostatic
process. In contrast, when imipramine was paired with prior REM
sleep restriction, the recovery of both pharmacological and physi-
ological REM sleep loss coincided, resulting in the recovery of all
A. McCarthy et al. / Neuropharmacology 108 (2016) 415e425424REM sleep lost.
4.5. Pharmacological mechanisms of REM sleep regulation
It is likely that a homeostat, distinct from that controlling NREM
sleep, is responsible for maintaining the amount of REM sleep over
time. Throughout physiological REM sleep restriction a deﬁcit in
REM sleep is created via an arousal, which was followed by a
rebound in REM sleep after release from the physiological REM
sleep restriction. However, the mechanisms by which aspects of
REM sleep are controlled are not well understood and no biological
substrate for the homeostat has yet been identiﬁed.
In the present study, SSRI induced REM sleep loss showed no
sign of recovery and the lack or presence of REM recovery was not
dose-dependent (unpublished Lilly data). Rats treated with SSRIs
awaken at the transition from NREM to REM (Kostyalik et al., 2014)
but SSRIs may only mask the electrophysiological signs of REM
sleep in rats, such as theta power and muscle atonia whilst its
function may remain intact. However, the SSRI treatments did not
reduce the recovery REM sleep induced by prior physiological REM
sleep deprivation. If REM sleep were masked, then this would be
expected to prevent the detection of both normal REM sleep and
recovery REM sleep.
These results can be placed in the context of the hypothesis
proposed by Franken that initiation and maintenance of REM sleep
are controlled by separate processes (Franken, 2002). SSRIs inhibit
REM sleep by reducing NREM e REM transitions (Kostyalik et al.,
2014), without altering the lengths of NREM sleep bouts. Franken
proposed that REM sleep initiation is a NREM sleep-dependent
sensitization process whose level rises during NREM sleep epi-
sodes. The SSRIs did not alter NREM sleep bout lengths, suggesting
that the sensitization process does not occur. However, why this is
the case remains unknown. Imipramine by contrast extends NREM
sleep bouts, which induces greater sensitization and reduces the
opportunity for REM sleep. This leads to the subsequent increase in
REM sleep during the recovery period. In the present study we have
not explored to what extent effects on REM sleep may be accom-
panied by changes in EEG slow wave activity in NREM sleep, or
attempts to enter REM sleep. Further exploratory analyses are
warranted given the interactions between the sleep states.
4.6. Limitations
Circadian factors may greatly inﬂuence the effects of pharma-
cological treatments as many treatments target circadian gene
products (Zhang et al., 2014). In this study, the REM sleep inhibition
is confounded to some degree by the timing of the light-dark cycle.
There is signiﬁcantly less REM sleep to inhibit during the dark
phase which may mask the true extent of REM inhibition by the
SSRIs. However, any REM sleep recovery would likely have been
observed over the subsequent 28 h, whichwas often evident during
the dark phase following physiological REM sleep restriction.
Further work to examine how circadian rhythmicity and the REM
sleep homeostat interact may provide clues to the mechanism of
REM sleep regulation. In addition to these effects, limitations in the
mathematical model of REM sleep recovery were apparent once
REM sleep homeostasis was blocked or strongly attenuated.
Without a signiﬁcant recovery, the exponential functionwas a poor
ﬁt to the data, leading to large errors. Furthermore, the exponential
recovery model may introduce systematic discrepancies between
the ﬁtted curve and the data, as observed in the REM sleep re-
striction recovery of the citalopram experiment between hours
4e6. Better models of sleep recovery should be ﬂexible enough to
cope with these situations. One potential model is a power law
function that could reduce the impact of selecting the initial onsetrecovery time upon the estimated rate of recovery.
The present ﬁndings may be relevant to potential side effects
and efﬁcacy associated with pharmacological REM sleep restriction
by antidepressant treatments. We hypothesise that SSRIs do not
engage the REM sleep homeostatic mechanism, which may mini-
mise the effects of lost REM sleep. In contrast, the TCA imipramine
does engage the REM sleep homeostat in a similar way to EEG-
driven feedback- REM sleep restriction, which may suggest mech-
anism of action -based differences inwhich antidepressants impact
sleep and potentially produce their antidepressant efﬁcacy.
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